LIVIVO - Search results -

Search results

Result 1 - 10 of total 114

Search options

Article ; Online: Newly diagnosed multiple myeloma: current treatment strategies, emerging therapeutic approaches and beyond.

Kocoglu, Mehmet H / Badros, Ashraf Z

2020 Volume 13, Issue 6, Page(s) 669–686

Abstract: Introduction: As we have just stepped into a new decade of hopes, the mountain of knowledge learned from multiple myeloma (MM) remains unmatched among cancers. In the last decade alone, this rapid-sequence learning curve has led to regulatory approvals ... ...

Abstract	Introduction: As we have just stepped into a new decade of hopes, the mountain of knowledge learned from multiple myeloma (MM) remains unmatched among cancers. In the last decade alone, this rapid-sequence learning curve has led to regulatory approvals of eight drugs with mechanisms of actions representing five different areas of cell biology some of which made to the frontline setting, sparking debates about how to best sequence them in the treatment continuum of induction, consolidation, and maintenance and gained momentum with the realization of the implications of an effective upfront therapeutic approach with potential impact on survival. Areas covered: This review was written with an intent to introduce the reader to the current treatment approach of a newly diagnosed myeloma patient and acquaint with promising targets and mechanistic strategies. Medline and clinicaltrials.gov databases (2000-2020) and relevant meetings (ASH, ASCO, EHA, ESMO, IMW) reports were queried and guidelines (IMWG) were reviewed to distill to expert opinion in an inundating field. Expert opinion: Future holds promise with new targets on the horizon. It is likely that the new age of myeloma will belong to quadruplets with the addition of acellular or cellular biologics to first-generation novel agents, leading to new paradigms.
MeSH term(s)	Antineoplastic Agents/therapeutic use ; Humans ; Multiple Myeloma/diagnosis ; Multiple Myeloma/drug therapy
Chemical Substances	Antineoplastic Agents
Language	English
Publishing date	2020-04-27
Publishing country	England
Document type	Journal Article ; Review ; Video-Audio Media
ZDB-ID	2516804-6
ISSN	1747-4094 ; 1747-4086
ISSN (online)	1747-4094
ISSN	1747-4086
DOI	10.1080/17474086.2020.1756258
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 6943: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article ; Online: Addressing the disparities: the approach to the African American patient with multiple myeloma.

Bhutani, Manisha / Blue, Brandon J / Cole, Craig / Badros, Ashraf Z / Usmani, Saad Z / Nooka, Ajay K / Bernal-Mizrachi, Leon / Mikhael, Joseph

Blood cancer journal

2023 Volume 13, Issue 1, Page(s) 189

Abstract: There are significant disparities with regards to incidence, timely diagnosis, access to treatment, clinical trial participation and health care utilization that negatively impact outcomes for African American patients with multiple myeloma. Health care ... ...

Abstract	There are significant disparities with regards to incidence, timely diagnosis, access to treatment, clinical trial participation and health care utilization that negatively impact outcomes for African American patients with multiple myeloma. Health care providers have a role in ameliorating these disparities with thoughtful consideration of historical, sociocultural, individual and disease characteristics that influence the care provided to African American patient population. This review by a group of experts committed to health disparity in multiple myeloma provides a snapshot of disparities at both biologic and non-biologic levels, barriers to clinical care, and best practices to ensure that African American patients receive the best care available.
MeSH term(s)	Humans ; Black or African American ; Delivery of Health Care ; Multiple Myeloma/diagnosis ; Multiple Myeloma/epidemiology ; Multiple Myeloma/therapy ; Patient Acceptance of Health Care ; Healthcare Disparities
Language	English
Publishing date	2023-12-18
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2600560-8
ISSN	2044-5385 ; 2044-5385
ISSN (online)	2044-5385
ISSN	2044-5385
DOI	10.1038/s41408-023-00961-0
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Prolonged Lenalidomide Induction Does Not Significantly Impair Stem Cell Collection in Multiple Myeloma Patients Mobilized With Cyclophosphamide or Plerixafor: A Report From The Covid Era.

Rybinski, Brad / Rapoport, Aaron P / Badros, Ashraf Z / Hardy, Nancy / Kocoglu, Mehmet

Clinical lymphoma, myeloma & leukemia

2022 Volume 22, Issue 8, Page(s) e716–e729

Abstract: Introduction: Induction therapy for multiple myeloma is traditionally capped at 6 cycles of lenalidomide due to concerns that longer treatment compromises the ability to collect sufficient stem cells for autologous stem cell transplantation (ASCT). ... ...

Abstract	Introduction: Induction therapy for multiple myeloma is traditionally capped at 6 cycles of lenalidomide due to concerns that longer treatment compromises the ability to collect sufficient stem cells for autologous stem cell transplantation (ASCT). However, during the COVID-19 pandemic, many of our patients received prolonged lenalidomide induction due to concerns about proceeding to ASCT. We investigated whether prolonged induction with lenalidomide affects the efficacy of stem cell collection among patients mobilized with cyclophosphamide and/or plerixafor. Patients and methods: This single center, retrospective study included patients who were treated with lenalidomide induction regimens, received mobilization with cyclophosphamide or plerixafor, and underwent apheresis in preparation for ASCT. 94 patients were included, 40 of whom received prolonged induction with >6 cycles of lenalidomide containing regimen. Results: Patients who received prolonged induction were more likely to require >1 day of apheresis (38% vs. 15%; OR 3.45; P = .0154), and there was a significant correlation between the duration of lenalidomide treatment and the apheresis time required to collect sufficient cells for transplant (R Conclusion: Among patients treated with >6 cycles of lenalidomide, mobilization augmented with cyclophosphamide and/or plerixafor will likely facilitate sufficient stem cell harvest to permit ASCT.
MeSH term(s)	Benzylamines/therapeutic use ; COVID-19 ; Cyclams/therapeutic use ; Cyclophosphamide/therapeutic use ; Hematopoietic Stem Cell Mobilization/methods ; Hematopoietic Stem Cell Transplantation ; Heterocyclic Compounds/pharmacology ; Heterocyclic Compounds/therapeutic use ; Humans ; Lenalidomide/therapeutic use ; Multiple Myeloma/drug therapy ; Pandemics ; Retrospective Studies ; Transplantation, Autologous
Chemical Substances	Benzylamines ; Cyclams ; Heterocyclic Compounds ; Cyclophosphamide (8N3DW7272P) ; Lenalidomide (F0P408N6V4) ; plerixafor (S915P5499N)
Language	English
Publishing date	2022-03-28
Publishing country	United States
Document type	Journal Article
ZDB-ID	2540992-X
ISSN	2152-2669 ; 2152-2650
ISSN (online)	2152-2669
ISSN	2152-2650
DOI	10.1016/j.clml.2022.03.013
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5903: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Lenalidomide in myeloma--a high-maintenance friend.

Badros, Ashraf Z

The New England journal of medicine

2012 Volume 366, Issue 19, Page(s) 1836–1838

MeSH term(s)	Antineoplastic Agents/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Female ; Humans ; Male ; Melphalan/administration & dosage ; Multiple Myeloma/drug therapy ; Prednisone/administration & dosage ; Stem Cell Transplantation ; Thalidomide/administration & dosage ; Thalidomide/analogs & derivatives ; Thalidomide/therapeutic use
Chemical Substances	Antineoplastic Agents ; Thalidomide (4Z8R6ORS6L) ; lenalidomide (F0P408N6V4) ; Melphalan (Q41OR9510P) ; Prednisone (VB0R961HZT)
Language	English
Publishing date	2012-05-10
Publishing country	United States
Document type	Comment ; Editorial
ZDB-ID	207154-x
ISSN	1533-4406 ; 0028-4793
ISSN (online)	1533-4406
ISSN	0028-4793
DOI	10.1056/NEJMe1202819
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.34: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Lessons Learned from Checkpoint Blockade Targeting PD-1 in Multiple Myeloma.

Lesokhin, Alexander M / Bal, Susan / Badros, Ashraf Z

Cancer immunology research

2019 Volume 7, Issue 8, Page(s) 1224–1229

Abstract: Immune checkpoints and agonists modulate ongoing, antigen-specific immune responses. Therapeutic blockade of CTLA-4, PD-1, and PD-L1 has proven to be an effective treatment approach for a subset of patients with a variety of cancers of epithelial, ... ...

Abstract	Immune checkpoints and agonists modulate ongoing, antigen-specific immune responses. Therapeutic blockade of CTLA-4, PD-1, and PD-L1 has proven to be an effective treatment approach for a subset of patients with a variety of cancers of epithelial, mesenchymal, or hematologic origin. In multiple myeloma, a B-cell lymphoid malignancy of terminally differentiated plasma cells, PD-1 pathway blockade is ineffective as a single agent. The initial promise in combination approaches utilizing anti-PD-1 with the immunomodulatory drugs, lenalidomide or pomalidomide, was not confirmed in randomized trials. Here, we explore available data for and against manipulation of the PD-1 pathway and other immune checkpoints in myeloma and highlight several promising concepts and challenges that face ongoing development of immunotherapeutics for this disease.
MeSH term(s)	Animals ; Antineoplastic Agents, Immunological/administration & dosage ; Antineoplastic Agents, Immunological/adverse effects ; Antineoplastic Agents, Immunological/therapeutic use ; Biomarkers, Tumor ; CTLA-4 Antigen/antagonists & inhibitors ; Clinical Trials as Topic ; Combined Modality Therapy/methods ; Drug Evaluation, Preclinical ; Humans ; Immunomodulation/drug effects ; Molecular Targeted Therapy ; Multiple Myeloma/drug therapy ; Multiple Myeloma/etiology ; Multiple Myeloma/pathology ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; T-Lymphocytes/drug effects ; T-Lymphocytes/immunology ; T-Lymphocytes/metabolism ; Treatment Outcome
Chemical Substances	Antineoplastic Agents, Immunological ; Biomarkers, Tumor ; CTLA-4 Antigen ; CTLA4 protein, human ; Programmed Cell Death 1 Receptor
Language	English
Publishing date	2019-08-01
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	2732489-8
ISSN	2326-6074 ; 2326-6066
ISSN (online)	2326-6074
ISSN	2326-6066
DOI	10.1158/2326-6066.CIR-19-0148
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 7022: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: The Role of Immunotherapy in Multiple Myeloma.

Kocoglu, Mehmet / Badros, Ashraf

Pharmaceuticals (Basel, Switzerland)

2016 Volume 9, Issue 1

Abstract: Multiple myeloma is the second most common hematologic malignancy. The treatment of this disease has changed considerably over the last two decades with the introduction to the clinical practice of novel agents such as proteasome inhibitors and ... ...

Abstract	Multiple myeloma is the second most common hematologic malignancy. The treatment of this disease has changed considerably over the last two decades with the introduction to the clinical practice of novel agents such as proteasome inhibitors and immunomodulatory drugs. Basic research efforts towards better understanding of normal and missing immune surveillence in myeloma have led to development of new strategies and therapies that require the engagement of the immune system. Many of these treatments are under clinical development and have already started providing encouraging results. We, for the second time in the last two decades, are about to witness another shift of the paradigm in the management of this ailment. This review will summarize the major approaches in myeloma immunotherapies.
Language	English
Publishing date	2016-01-14
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2193542-7
ISSN	1424-8247
ISSN	1424-8247
DOI	10.3390/ph9010003
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Biologic Implications of t(11;14) in Multiple Myeloma Explained With a Case of Refractory Disease Sensitive to Venetoclax.

Soleimani, Arshia / Koka, Madhurima / Singh, Zeba N / Kesari, Vivek / Badros, Ashraf

Clinical lymphoma, myeloma & leukemia

2020 Volume 20, Issue 9, Page(s) e556–e559

MeSH term(s)	Adult ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Bridged Bicyclo Compounds, Heterocyclic/pharmacology ; Bridged Bicyclo Compounds, Heterocyclic/therapeutic use ; Humans ; Male ; Multiple Myeloma/complications ; Multiple Myeloma/drug therapy ; Multiple Myeloma/pathology ; Sulfonamides/pharmacology ; Sulfonamides/therapeutic use
Chemical Substances	Antineoplastic Agents ; Bridged Bicyclo Compounds, Heterocyclic ; Sulfonamides ; venetoclax (N54AIC43PW)
Language	English
Publishing date	2020-06-14
Publishing country	United States
Document type	Case Reports
ZDB-ID	2540992-X
ISSN	2152-2669 ; 2152-2650
ISSN (online)	2152-2669
ISSN	2152-2650
DOI	10.1016/j.clml.2020.05.028
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5903: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: In the age of novel therapies, what defines high-risk multiple myeloma?

Badros, Ashraf Z

Journal of the National Comprehensive Cancer Network : JNCCN

2010 Volume 8 Suppl 1, Page(s) S28–34

Abstract: Multiple myeloma is characterized by clinical and biologic heterogenicity. Recently, genetic analysis has provided predictable prognosis across different types of treatment. These advances have allowed patients to be categorized into different risk ... ...

Abstract	Multiple myeloma is characterized by clinical and biologic heterogenicity. Recently, genetic analysis has provided predictable prognosis across different types of treatment. These advances have allowed patients to be categorized into different risk groups and have been particularly useful in defining a high-risk group with short survival after standard- and high-dose chemotherapies. Preliminary studies have shown promising outcomes after the use of novel agents, such as bortezomib, thalidomide, and lenalidomide in high-risk patients, including those eligible for autologous stem cell transplantation and those who cannot or will not undergo transplantation. The application of risk-based therapy and the potential of the new agents to abrogate the influence of adverse prognostic features may improve outcomes in these patients.
MeSH term(s)	Antineoplastic Agents/therapeutic use ; Hematopoietic Stem Cell Transplantation ; Humans ; Multiple Myeloma/diagnosis ; Multiple Myeloma/therapy ; Prognosis ; Risk Assessment ; Risk Factors
Chemical Substances	Antineoplastic Agents
Language	English
Publishing date	2010-01-14
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2250759-0
ISSN	1540-1405
ISSN	1540-1405
DOI	10.6004/jnccn.2010.0114
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6365: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: The role of maintenance therapy in the treatment of multiple myeloma.

Badros, Ashraf Z

Journal of the National Comprehensive Cancer Network : JNCCN

2010 Volume 8 Suppl 1, Page(s) S21–7

Abstract: Maintenance therapy in multiple myeloma has been under investigation for more than 3 decades, without evidence of clear benefit until recently. Chemotherapy maintenance offers no benefit after conventional or high-dose treatment. Interferon-based ... ...

Abstract	Maintenance therapy in multiple myeloma has been under investigation for more than 3 decades, without evidence of clear benefit until recently. Chemotherapy maintenance offers no benefit after conventional or high-dose treatment. Interferon-based maintenance is associated with minimal improvements in clinical outcomes, but is poorly tolerated. Results of corticosteroid maintenance studies have been conflicting; at least one randomized trial showed improved survival with prednisone maintenance after conventional chemotherapy. The role of the novel agents thalidomide, lenalidomide, and bortezomib as maintenance is emerging. Most reported maintenance studies have evaluated thalidomide, alone or in combination with a corticosteroid. Several of these studies suggest that thalidomide-based maintenance prolongs overall survival after autologous stem cell transplantation. Important questions that have not yet been resolved include the optimal dose and duration of thalidomide, whether clinical benefit depends on response to induction therapy and risk for relapse, and whether reported benefits are caused by cytoreduction or eradication of minimal residual disease, especially with bortezomib maintenance. Ongoing randomized trials are evaluating lenalidomide and bortezomib maintenance therapies to better define the role of these drugs as maintenance in multiple myeloma.
MeSH term(s)	Antineoplastic Agents/therapeutic use ; Clinical Trials as Topic ; Hematopoietic Stem Cell Transplantation ; Humans ; Multiple Myeloma/drug therapy ; Neoplasm, Residual/therapy ; Prognosis ; Treatment Outcome
Chemical Substances	Antineoplastic Agents
Language	English
Publishing date	2010-01-14
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2250759-0
ISSN	1540-1405
ISSN	1540-1405
DOI	10.6004/jnccn.2010.0113
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6365: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Immune-mediated facial nerve paralysis in a myeloma patient post B-cell maturation antigen-targeted chimeric antigen receptor T cells.

Kathari, Yamini K / Ahmad, Haroon / Kallen, Michael E / Koka, Rima / Omili, Destiny / Iraguha, Thierry / Clement, Jean / Pham, Lily / Khalid, Mazhar / Fan, Xiaoxuan / Gebru, Etse / Lesho, Patricia / Park, Esther / Dishanthan, Nishanthini / Baker, Jillian M / Dietze, Kenneth A / Hankey, Kim G / Badros, Ashraf / Yared, Jean A /

Dahiya, Saurabh / Hardy, Nancy M / Kocoglu, Hakan / Luetkens, Tim / Rapoport, Aaron P / Atanackovic, Djordje

Haematologica

2024 Volume 109, Issue 2, Page(s) 682–688

MeSH term(s)	Humans ; Multiple Myeloma/complications ; Multiple Myeloma/therapy ; Receptors, Chimeric Antigen ; B-Cell Maturation Antigen ; Facial Nerve ; Immunotherapy, Adoptive/adverse effects ; T-Lymphocytes ; Paralysis
Chemical Substances	Receptors, Chimeric Antigen ; B-Cell Maturation Antigen
Language	English
Publishing date	2024-02-01
Publishing country	Italy
Document type	Journal Article
ZDB-ID	2333-4
ISSN	1592-8721 ; 0017-6567 ; 0390-6078
ISSN (online)	1592-8721
ISSN	0017-6567 ; 0390-6078
DOI	10.3324/haematol.2023.283296
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.76: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito